PEOPLE - Changes at Gambro Blood Component Technology:
This article was originally published in Clinica
Gambro has announced that Ed Wood, president of Gambro Blood Component Technology (BCT), has left the company. Gambro said that it is "entering an exciting new phase of expansion and growth" which required "a new breed of global leadership". Gary Heath, head of the BCT management team, will serve as acting president until a replacement is found.
You may also be interested in...
TTS Pharma CEO Mark Tucker discusses his ambition to bring a legal CBD oil to the UK market, following the recent submission of a European Union novel food application.
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.